Latest & greatest articles for atenolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atenolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atenolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atenolol

21. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group.

Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. 9251545 1997 08 28 1997 08 28 2013 11 21 0959-8138 315 7101 1997 Jul 19 BMJ (Clinical research ed.) BMJ Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. 154 (...) -9 To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension. Randomised multicentre trial over 48 weeks with double blind comparison of treatments. 48 centres in four countries. 868 patients with essential hypertension (diastolic blood pressure 95-120 mm Hg) Initial treatment (step 1) consisted of 12.5 mg hydrochlorothiazide (n = 215), 25 mg atenolol (n = 215), 10 mg nitrendipine (n = 218), or 5 mg

BMJ1997 Full Text: Link to full Text with Trip Pro

22. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group.

Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. 8929262 1996 12 06 1996 12 06 2013 11 21 0028-4793 335 23 1996 Dec 05 The New England journal of medicine N. Engl. J. Med. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. 1713-20 Perioperative myocardial ischemia is the single most important potentially (...) reversible risk factor for mortality and cardiovascular complications after noncardiac surgery. Although more than 1 million patients have such complications annually, there is no effective preventive therapy. We performed a randomized, double-blind, placebo-controlled trial to compare the effect of atenolol with that of a placebo on overall survival and cardiovascular morbidity in patients with or at risk for coronary artery disease who were undergoing noncardiac surgery. Atenolol was given

NEJM1996

23. Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics.

Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics. 1581716 1992 06 17 1992 06 17 2013 11 21 0959-8138 304 6832 1992 Apr 11 BMJ (Clinical research ed.) BMJ Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics. 946-9 To compare the effects of uteroplacental circulation of two beta adrenoceptor blockers, atenolol (cardioselective) and pindolol (non-selective with intrinsic sympathomimetic (...) activity). Controlled double blind double dummy study. Departments of obstetrics and gynaecology in two Swedish university hospitals. 29 women with pregnancy induced hypertension in the third trimester, 13 randomised to atenolol and 16 to pindolol. Pulsatility index in fetal aorta, umbilical artery, and maternal arcuate artery. Volumetric blood flow in fetal aorta and umbilical vein. Mean arterial blood pressure decreased by 9.0 (95% confidence interval -13.0 to -5.0) mm Hg in the atenolol group

BMJ1992 Full Text: Link to full Text with Trip Pro

24. beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination.

beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. 1747577 1992 01 21 1992 01 21 2013 11 21 0959-8138 303 6810 1991 Nov 02 BMJ (Clinical research ed.) BMJ beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. 1100-4 To determine the effects of the beta 1 selective adrenoceptor blocker atenolol, the dihydropyridine calcium antagonist nifedipine (...) , and the combination of atenolol plus nifedipine on objective and subjective measures of walking performance and foot temperature in patients with intermittent claudication. Randomised controlled double blind four way crossover trial. Royal Hallamshire Hospital, Sheffield. 49 patients (40 men) aged 39-70 with chronic stable intermittent claudication. Atenolol 50 mg twice daily; slow release nifedipine 20 mg twice daily; atenolol 50 mg plus slow release nifedipine 20 mg twice daily; placebo. Each treatment

BMJ1991 Full Text: Link to full Text with Trip Pro

25. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina.

Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. 1681355 1991 11 21 1991 11 21 2016 11 23 0140-6736 338 8774 1991 Oct 26 Lancet (London, England) Lancet Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. 1036-9 Many patients with angina pectoris whose symptoms are not completely controlled by beta-blockers are treated with several types of drugs, but it is not clear whether addition of a calcium (...) -channel antagonist and/or a nitrate confers any advantage over beta-blockade alone. 18 patients receiving atenolol for stable angina pectoris completed a double-blind, randomised, crossover trial of atenolol treatment plus placebo, isosorbide mononitrate, nifedipine, and mononitrate and nifedipine (triple therapy). The patients were assessed subjectively and by treadmill exercise testing and 24 h ambulatory electrocardiographic recordings at the end of each 4-week treatment period. There were

Lancet1991

26. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.

Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. 1932973 1991 12 17 1991 12 17 2013 11 21 0959-8138 303 6806 1991 Oct 05 BMJ (Clinical research ed.) BMJ Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. 821-4 To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic (...) origin. Prospective, double blind, randomised 16 week study after a pretreatment period of at least three weeks. Outpatient nephrology and hypertension unit. 27 patients with proteinuria (greater than 300 mg protein/day) of non-diabetic origin, moderately impaired renal function (creatinine clearance 30-90 ml/min), and a pretreatment diastolic blood pressure of greater than 80 mm Hg. Treatment with enalapril (10 mg/day, adjusted between 5 and 40 mg, if necessary) or atenolol (50 mg/day, adjusted

BMJ1991 Full Text: Link to full Text with Trip Pro

27. Atenolol in essential hypertension during pregnancy.

Atenolol in essential hypertension during pregnancy. 2242456 1991 01 03 1991 01 03 2016 10 19 0959-8138 301 6752 1990 Sep 22 BMJ (Clinical research ed.) BMJ Atenolol in essential hypertension during pregnancy. 587-9 To determine the effect of atenolol on the outcome of pregnancy in women with essential hypertension. Prospective, randomised, double blind, placebo controlled study. Hospital clinic. 33 Women with mild essential hypertension (systolic blood pressure 140-170 mm Hg or diastolic (...) pressure 90-110 mm Hg on two occasions at least 24 hours apart) consecutively referred to two obstetric medical clinics. Four patients in the placebo group were withdrawn from the study: control of blood pressure was inadequate in two, one developed breathlessness, and one changed her mind about participating. The mean gestation in the 29 remaining women on entry to the study was 15.9 weeks. Blood pressure and birth weight. 14 Women received placebo. 15 Women received atenolol 50 mg daily initially

BMJ1990 Full Text: Link to full Text with Trip Pro

28. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.

Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. 2500169 1989 08 09 1989 08 09 2013 11 21 0959-8138 298 6681 1989 Apr 29 BMJ (Clinical research ed.) BMJ Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. 1152-7 To compare the effects (...) of metoprolol and atenolol on carbohydrate and lipid metabolism and on insulin response to an intravenous glucose load. Randomised, double blind, double dummy, controlled crossover trial. University Hospital, Uppsala, Sweden. 60 Patients with primary hypertension (diastolic blood pressure when resting supine 95-119 mm Hg on at least two occasions during four to six weeks of treatment with placebo) randomised to receive either metoprolol (n = 30) or atenolol (n = 30) during the first treatment period

BMJ1989 Full Text: Link to full Text with Trip Pro

29. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication.

Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. 2887941 1987 10 20 1987 10 20 2015 06 16 0140-6736 2 8560 1987 Sep 19 Lancet (London, England) Lancet Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. 650-3 In a six month placebo-controlled cross-over trial twenty patients with hypertension and peripheral arterial disease (...) were randomised to captopril 25 mg twice daily, atenolol 100 mg once daily, labetalol 200 mg twice daily, or pindolol 10 mg twice daily for one month. Although all treatments were equally effective at lowering blood pressure, pain-free and maximum walking distances on a treadmill were decreased by atenolol, labetalol, and pindolol, but not by captopril. Post-exercise calf blood flow availability was impaired by atenolol, labetalol, and pindolol, but not by captopril. Despite ancillary

Lancet1987

30. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway.

Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. 2870352 1986 05 16 1986 05 16 2015 06 16 0140-6736 1 8486 1986 Apr 19 Lancet (London, England) Lancet Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. 872-5 Enalapril, atenolol, and hydrochlorothiazide were compared in a double-blind randomised parallel study (...) in general practice. 436 patients with mild to moderate hypertension were included at 76 centres. A two-week placebo run-in period was followed by 16 weeks of monotherapy. The initial doses were: enalapril 20 mg; atenolol 50 mg; and hydrochlorothiazide 25 mg. These were doubled if treatment was not effective after 4 weeks. Adverse reactions were the main reason for withdrawal from the study (9 on enalapril, 19 on atenolol, and 8 on hydrochlorothiazide). Systolic and diastolic blood pressures were

Lancet1986

31. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. 2873379 1986 08 11 1986 08 11 2015 06 16 0140-6736 2 8498 1986 Jul 12 Lancet (London, England) Lancet Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. 57-66 Between mid-1981 and Jan 1, 1985, 16 (...) 027 patients entering 245 coronary care units at a mean of 5.0 h after the onset of suspected acute myocardial infarction were randomised either to a control group or to a group receiving atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days). Vascular mortality during the treatment period (days 0-7) was significantly lower (2p less than 0.4) in the treated group, 313/8037 (3.89%) versus 365/7990 (4.57%), but this 15% difference has wide 95% confidence limits (from about zero

Lancet1986

32. Randomized clinical trial of atenolol in patients with alcohol withdrawal.

Randomized clinical trial of atenolol in patients with alcohol withdrawal. 2863754 1985 10 24 1985 10 24 2013 11 21 0028-4793 313 15 1985 Oct 10 The New England journal of medicine N. Engl. J. Med. Randomized clinical trial of atenolol in patients with alcohol withdrawal. 905-9 We conducted a randomized, double-blind clinical trial of atenolol as compared with placebo in the treatment of patients hospitalized with the alcohol withdrawal syndrome. In addition to receiving customary therapy, 61 (...) patients were randomly assigned to receive atenolol, and 59 to receive placebo. Outcome was assessed daily by the measurement of nine features in three categories: vital signs, clinical signs (e.g., tremor), and behavioral signs (e.g., agitation and anxiety). Compared with placebo patients, atenolol patients had a significant reduction in the mean length of hospital stay (four as compared with five days, P less than 0.02). On each treatment day, significantly fewer patients receiving atenolol required

NEJM1985

33. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine.

Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. 6366561 1984 04 26 1984 04 26 2013 11 21 0028-4793 310 15 1984 Apr 12 The New England journal of medicine N. Engl. J. Med. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. 951-4 To determine whether cigarette smoking affects the results of drug treatment for angina, we studied 10 cigarette smokers with angina who were given placebo, nifedipine (60 mg per day (...) ), propranolol (240 mg per day), and atenolol (100 mg per day), each for one week. The four-week double-blind study was repeated with the same randomly determined order of drug sequences, after all 10 subjects had stopped smoking. Before and after the subjects stopped smoking, all three drugs significantly reduced the frequency of angina, as measured with angina diaries, and improved the results of maximal exercise testing and 48-hour ambulatory monitoring of ST segments (P less than 0.01). However, during

NEJM1984

34. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension.

Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. 6131164 1983 04 21 1983 04 21 2015 06 16 0140-6736 1 8322 1983 Feb 26 Lancet (London, England) Lancet Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. 431-4 Atenolol was compared with placebo in a randomised and double-blind prospective study of 120 women with mild to moderate pregnancy-associated hypertension who were also initially managed conventionally by bed rest (...) . Atenolol given once daily significantly reduced blood-pressure, prevented proteinuria, and reduced the number of hospital admissions. Loss of blood-pressure control leading to withdrawal from the study was commoner among the placebo group, whose babies had a high morbidity. Respiratory distress syndrome occurred only in the placebo group. Intrauterine growth retardation, neonatal hypoglycaemia, and hyperbilirubinaemia occurred with the same frequency in the two groups. Neonatal bradycardia was more

Lancet1983

35. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome.

Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. 6112564 1981 07 23 1981 07 23 2015 06 16 0140-6736 1 8232 1981 Jun 06 Lancet (London, England) Lancet Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. 1225-8 A randomised, double-blind, placebo controlled study of morbidity and mortality was carried out using heparin, atenolol, and a combination of both drugs, in 214 patients (...) with the intermediate coronary syndrome. During the trial period, transmural myocardial infarction developed in 9 (17%) out of 54 patients on placebo, 8 (13%) out of 60 on atenolol, 1 (2%) out of 51 on heparin, and 2 (4%) out of 49 on heparin and atenolol combined (p = 0.024). The improved prognosis in the heparin-treated patients was was maintained at follow-up. All five deaths occurred among patients who did not receive heparin. These results show that intravenous heparin therapy was of benefit in preventing

Lancet1981

36. Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial.

Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. 6105436 1980 10 27 1980 10 27 2015 06 16 0140-6736 2 8189 1980 Aug 09 Lancet (London, England) Lancet Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. 273-6 214 patients were studied in a randomised trial to determine whether administraiton of intravenous atenolol within 12 hours of chest pain reduced (...) eventual infarct size, as estimated by cumulative enzyme release and by ECG changes. 135 patients already had ECG evidence of infarction at entry; 72 received atenolol which significantly decreased subsequent enzyme release (atenolol and control means = 121 IU, SE +/- 10 and 177 IU, SE +/- 17; 2p < 0.005) and enhanced R-wave preservation (atenolol and control means = 46% +/- 3 and 36% +/- 3; 2p < 0.02). 79 patients had no evidence of infarction at entry; 44 did not receive atenolol and 27

Lancet1980

37. Effect of atenolol on recovery of the electrocardiographic signs of myocardial infarction.

Effect of atenolol on recovery of the electrocardiographic signs of myocardial infarction. 90965 1979 12 29 1979 12 29 2015 06 16 0140-6736 2 8148 1979 Oct 27 Lancet (London, England) Lancet Effect of atenolol on recovery of the electrocardiographic signs of myocardial infarction. 868-9 The most notable changes in the 35-lead precordial electrocardiogram in 22 subjects in the first 6--12 months after acute myocardial infarction were a reduction in the amplitude of Q waves and a significant (...) increase in the amplitude of the R waves. Patients who, in a random trial, had been given 100 mg atenolol daily from admission showed a significantly greater recovery in R-wave amplitude and decrease in Q waves than patients given placebo. It is concluded that atenolol improves the recovery of the electrocardiographic signs of myocardial infarction. Yusuf S S Lopez R R Sleight P P eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0

Lancet1979